BC-LI-0186
BC-LI-0186 is a potent, selective inhibitor of the LRS-RagD interaction with a Kd of 42.1 nM. It suppresses mTORC1 signaling by this mechanism, inhibiting the growth of rapamycin-resistant cancer cells in vitro, and is applied in lung cancer research.
Product Specifications
CAS Number
695207-56-8
Product Name Alternative
Inhibitor, leucyl-tRNA synthetase, Leucyl-tRNA synthetase, H460, lung cancer, KRAS G12D, inhibit, A549, 4- (2,3-dimethyl-5-oxo-4-propan-2-ylpyrazol-1-yl) -N- (2-phenoxyethyl) benzenesulfonamide, BC LI 0186, BC-LI 0186, BCLI0186, BC-LI0186, BC-LI-0186, Aminoacyl-tRNA Synthetase, RagD, rapamycin-resistant, Ras-related GTP-binding protein D (RagD), tRNA Synthetase, aaRS
Purity
99.17% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (9.31 mM) ; DMSO:100 mg/mL (232.81 mM)
Smiles
CC (C) c1c (C) n (C) n (-c2ccc (cc2) S (=O) (=O) NCCOc2ccccc2) c1=O
Molecular Formula
C22H27N3O4S
Molecular Weight
429.53
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
